Rob Dillard

DocwireNews

The findings of a new study<a href="https://linkinghub.elsevier.com/retrieve/pii/S0092867419313212"> published</a> in the journal Cell&nbsp;<a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/glioblastoma-bloodtest/">suggest that</a> glioblastoma organoids could serve as effective models to rapidly test personalized treatment strategies.&ldquo;While we&rsquo;ve made important strides in glioblastoma research, preclinical and clinical challenges persist, keeping us from getting closer to more effective treatments,&rdquo; said senior author Hongjun Song, PhD, Perelman Professor of Neuroscience in the Perelman School of Medicine at the University of Pennsylvania in a <a href="https://www.eurekalert.org/pub_releases/2019-12/uops-bto122319.php">press release</a> about the study. &ldquo;One hurdle is the ability to recapitulate the tumor to not only better understand its complex characteristics, but also to determine what therapies post-surgery can fight it in a timelier manner.&rdquo;To conduct this study, the researchers extracted fresh tumor specimens from 52 patients to &ldquo;grow&rdquo; corresponding tumor organoids in the lab. The results showed that the overall success rate for generating glioblastoma organoids (GBOs) was 91%, with almost 67% percent of tumors expressing the&nbsp;IDH1&nbsp;mutation, and 75 percent for recurrent tumors, within two weeks. These tumor glioblastoma organoids can also be biobanked and recovered later for analyses.Moreover, the researchers conducted a molecular analyses in 12 patients to establish that these new GBOs had largely retained features from the primary tumor in the patient. Subsequently the researchers transplanted eight GBO samples into adult mouse models, which displayed rapid and aggressive detection of cancer cells while maintaining key mutation expression up to three months later. Importantly, a major hallmark of GBM &mdash; the infiltration of tumor cells into the surrounding brain tissue &mdash; was observed in the mouse models.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
<a href="https://twitter.com/hashtag/Brain?src=hash&amp;ref_src=twsrc%5Etfw">#Brain</a> <a href="https://twitter.com/hashtag/tumor?src=hash&amp;ref_src=twsrc%5Etfw">#tumor</a> organoids may be key to time-sensitive treatments for glioblastomas <a href="https://twitter.com/PennMedicine?ref_src=twsrc%5Etfw">@pennmedicine</a> <a href="https://twitter.com/CellCellPress?ref_src=twsrc%5Etfw">@CellCellPress</a> <a href="https://t.co/p0OTSphZfk">https://t.co/p0OTSphZfk</a>
&mdash; Medical Xpress (@medical_xpress) <a href="https://twitter.com/medical_xpress/status/1210228803932475397?ref_src=twsrc%5Etfw">December 26, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&ldquo;These results highlight the potential for testing and treating glioblastomas with a personalized approach. The ultimate goal is to work towards a future where we can study a patient&rsquo;s organoid and test which CAR T cell is going to be the best against their tumor, in real time.&rdquo; O&rsquo;Rourke said. &ldquo;A shorter-term goal, given the heterogeneity of glioblastomas, is that in vitro testing of various therapeutic options may also help refine patient enrollment in clinical trials, by more accurately defining mutations and selecting the appropriate, available targeted therapies for each.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Brain Tumor Organoids May be Key to Time-sensitive Treatments for Glioblastomas
Lab-grown brain organoids developed from a patient&rsquo;s own glioblastoma, the most aggressive and common form of brain cancer, may hold the answers on how to best trea&hellip;
More: <a href="https://t.co/yn7uIKgh0i">https://t.co/yn7uIKgh0i</a> <a href="https://t.co/1PHjtcdctx">pic.twitter.com/1PHjtcdctx</a>
&mdash; NobleResearch (@NobleResearch) <a href="https://twitter.com/NobleResearch/status/1211693800239685632?ref_src=twsrc%5Etfw">December 30, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>https://twitter.com/Gander_News_d6/status/1210655322769104897&nbsp;

Jayme Locke, MD, MPH

Joel M. Topf, MD, FACP

The Promise of Xenotransplantation

NKF Spring Clinical Meetings 2025

Leah Lawrence

Real-World Data Backs Invasive DFS as Surrogate Endpoint for OS in EBC

HR Breast Cancer

Sacituzimab Govitecan Showed Modest Activity for CNS Metastases

Triple-Negative Breast Cancer

Latest News

Brain Tumor Organoids Key in Treating Glioblastomas

Oncology

The findings of a new study published in the journal Cell suggest that glioblastoma organoids could serve as effective models to rapidly test personalized treatment ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe